- Home
- IMUX vs DIBS Comparison
IMUX vs DIBS Comparison
Compare IMUX & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | DIBS |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.6M | 162.5M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMUX | DIBS |
|---|---|---|
| Price | $14.29 | $4.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $36.00 | $7.00 |
| AVG Volume (30 Days) | 253.5K | ★ 291.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | 22.45 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $89,620,000.00 |
| Revenue This Year | N/A | $3.12 |
| Revenue Next Year | N/A | $1.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.54 |
| 52 Week Low | $0.51 | $2.37 |
| 52 Week High | $14.69 | $6.62 |
Technical Indicators
Market Signals| Indicator | IMUX | DIBS |
|---|---|---|
| Relative Strength Index (RSI) | 80.73 | 45.30 |
| Support Level | $0.74 | $4.38 |
| Resistance Level | N/A | $4.87 |
| Average True Range (ATR) | 1.10 | 0.29 |
| MACD | -0.13 | 0.06 |
| Stochastic Oscillator | 83.64 | 81.30 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.